As with many other companies Eli Lilly and Company (NYSE:LLY) makes use of debt. But the more important question is: how much ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best ... sectors ...

in everything about Eli Lilly and Company. If you've got follow-up questions or things we didn't cover in enough detail today in the Q&A. Please follow-up with the IR team. Mike Spre leads that now.

Eli Lilly and Company (NYSE:LLY)’s Zepbound recently received FDA approval for treating obstructive sleep apnea in obese patients. This approval allows Medicare Part D plans to cover the drug ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... The oncology sector covers the entire cancer care process, from diagnosis to treatment. Pharmaceutical and ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years for the Company.

Should You Invest in Eli Lilly and Company (LLY)? Before you invest in ... with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.) ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant ... Biden administration for Medicare to cover weight loss drugs, Ricks said it remains ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Eli Lilly and Company (NYSE:LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to... Analysts at ...